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patient-centered treatment assessments and growth in risk sharing assessments
will further increase the need for real-world PRO data.
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OBJECTIVES: Scales measuring perceptions of pain can include numeric rating
scales (NRS), visual analogue scales (VAS) and descriptor scales using words (ad-
jectival). With the increased use of electronic data capture in clinical trial settings,
such scales have been migrated to numerous platforms. After conducting a brief
literature review, there was found to be a lack of research on the impact that
migration of such pain scales can have on the efficacy of the scales. The objective
of this study was to deploy three pain scales in different formats and on different
platforms, and to explore preferences and perceived differences in patients who
experience daily pain. METHODS: Twelve participants diagnosed with a range of
conditions resulting in pain were interviewed in a qualitative interview setting. All
participants completed three pain scales in different formats: NRS (11-, 9-, and
7-points; portrait/ landscape), VAS (horizontally/ vertically; portrait/ landscape)
and adjectival scale (increasing/ decreasing severity). All scales were presented in
three modes of administration: paper, handheld device and tablet device. Partici-
pants were asked about perceived differences and their preferences of the different
scales, formats, and modes of administration. RESULTS: The NRS and adjectival
scale were preferred equally (n5). Participants expressed an almost unanimous
preference for the 11-point NRS and increasing severity adjectival scale, across all
administration modes. In contrast, the VAS was the least preferred scale (n7) due
to difficulty with interpretation. Participants expressed no usability problems with
the tablet or handheld devices, but the tablet was preferred overall because of the
bigger screen. CONCLUSIONS: Although the sample size makes generalising these
findings difficult, this exploratory study suggests that the preferred pain scales
may provide higher quality data as they are easier to interpret, and therefore mi-
nimise error and patient burden. Further evidence, particularly quantitative, is
required to support these preliminary findings.
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OBJECTIVES: Effective translation and adaptation of neuropsychological assess-
ments is paramount to the successful collection of data in a global context. The
structure and content of neuropsychological assessments requires specific pro-
cesses for translation and adaptation to ensure appropriate understanding in each
target language. Word list adaptation requires particular consideration, as various
criteria must be met within and between wordlists – including but not limited to
frequency, familiarity and cultural relevance to the target population, number of
syllables, and avoidance of homonyms and repeated words. This review highlights
important considerations for creation of target language word lists, and solutions
for determining appropriate adaptation methodologies. METHODS: A review of
previous translations of neuropsychological assessments, such as the ADAS, FC-
SRT, RBANS, MoCA, and MMSE, was performed. A review of translation procedures,
developer involvement, guidelines for adaptation, translation methodology, lin-
guistic decisions, and word list creation was conducted. RESULTS: Key solutions to
ensure successful adaptation of wordlists include: 1) Outline all criteria used to
develop the English word lists and assessment, 2) Create clear guidelines for adap-
tation of word lists in collaboration with the developer, if guidelines are not already
available, 3) Employ a specialized project team of project managers, native-speak-
ing medical linguists, and native-speaking neuropsychologists possessing exten-
sive expertise in the relevant neuropsychological assessments. 4) Depending upon
the assessment and the context of use, additional testing of the word lists with
local populations to ensure comprehension may be warranted. CONCLUSIONS:
Neuropsychological assessments and word lists require specialized translation
and adaptation methodologies to ensure appropriate comprehension by the target
population. Developer involvement in the creation of adaptation guidelines, and
neuropsychologist involvement in the adaptation process are critical to ensuring
adaptation is conducted appropriately. Further research is required to outline clear
guidelines for situations requiring additional testing of the word lists with local
populations to ensure comprehension.
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OBJECTIVES:Mapping or cross-walking is an accepted methodology for calculating
utilities. Different models have been proposed for mapping from disease-specific
quality-of-life (QOL) measures to generic QOL measures. Much of this work has
been done using data from rheumatoid arthritis cohorts and using measures spe-
cific to RA. The objectives of this study are to test various statistical models to
determine which provides the best fit for a psoriatic arthritis (PsA) cohort using
both newly developed composite disease measures and established measures. The
study also aimed to determine whether the composite disease measures provide a
better estimate of utility over other measures and which components of the com-
posite measures influence the relationship with QOL. METHODS: The data was
made available from the Group for Research and Assessment of Psoriasis and Pso-
riatic Arthritis (GRAPPA) which collected data from an international cohort of PsA
patients. Different regression models were used to estimate the relationship be-
tween the generic QOL measure, SF-6D and disease specific measures (HAQ,Com-
posite Disease Activity Index (CPDAI), Psoriatic ArthritiS Disease Activity Score
(PASDAS) and the Arithmetic Mean Desirability Function Score (AMDF). Model fit
was determined using the R2 statistic, root mean square error, Akaike information
criterion; regression coefficients are also presented. RESULTS: The optimal model
for each of the disease specific measures and SF-6D was a multiple regression
model. The difference in model fit between the linear and multiple regression
models was greatest for the composite disease measures specific to PsA. The CPDAI
and AMDF provided the best fit to utility score followed by the PASDAS.
CONCLUSIONS: PsA is a heterogeneous disease for which composite disease mea-
sures may be more appropriate than measures such as the HAQ. This study pro-
vides mapping coefficients, allowing utility estimation from these measures which
may be collected in trials where no preference-based utility measure has been
used.
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OBJECTIVES: To highlight some of the common areas that require particular atten-
tion when preparing clinical outcome assessment (COA) dossiers, suitable for FDA
regulatory label claims, with a particular focus on clinician-reported outcome
(ClinRO) measures. The FDA has provided guidance for the use of Patient-Reported
Outcome (PRO) measures for relevant endpoints in clinical trials to support label
claims (FDA, 2009). Although several authors have indicated that the standards
used to evaluate PRO’s will apply to all COA’s (Burke, 2011; Gwaltney, 2012), the FDA
have not published guidelines on ClinRO measures to support label claims. This is
surprising given that the ratio of label claims based on ClinRO’s is approximately
three ClinRO’s to every PRO measure (Burke, 2010). METHODS: We conducted a
review of the literature to ascertain the general level of use of ClinRO’s and to find
examples of widely used ClinRO’s. The available evidence for these ClinRO’s was
then assessed by the standards of the PRO guidance, specifically in relation to
content and construct validity, reliability and other psychometric properties.
RESULTS: The literature review revealed that ClinRO’s are common endpoints in
clinical trials. However, it was also apparent from the sample of ClinRO’s reviewed,
that they fail to meet the evaluative standards prescribed by the FDA particularly in
being “well defined and reliable”. CONCLUSIONS: ClinRO’s used as endpoints in
clinical trials to support FDA label claims may lack the required evidence set out in
the FDA PRO guidance document. Specifically, many ClinRO’s have been developed
by clinicians, and widely accepted by clinical peers, without undergoing psycho-
metric evaluation. If the FDA were to evaluate ClinRO’s to the same standards as
PRO’s, the ratio of label claims between ClinRO’s and PROs may decrease signifi-
cantly.
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OBJECTIVES: Osteoarthritis (OA) also known as degenerative arthritis or degener-
ative joint disease, is a group of mechanical abnormalities involving degradation of
joints. The daily-life of OA patient is considerably disturbed. The burden’s concept
assesses the individual burden, measuring the patient’s disability generated by the
disease in a broad sense.The aim of our study was to explore, using a question-
naire, how the burden of the OA affected a daily life, with the objective to better
anticipate difficulties and thus provide better care METHODS: The development of
the questionnaire we propose here was inspired by the construction of general
QoL- questionnaires. Two steps are required for the development:, the creation in
three stages following a strict methodological process involving a multidisciplinary
team (doctors, social workers) and patients with OA who were interviewed; Sec-
ondly, the validation of the questionnaire by testing its reliability, its construct
validity and its reproducibility. A cognitive debriefing was conducted to ensure its
reproducibility. RESULTS: A population of 198 patients with OA was enrolled to
answer to the questionnaire,( with SF12 and PGWI). We obtain a questionnaire
called “Burden-Osteoartritis-New-Scale-BONeS”. Exploratory assessments real-
ized with a population showed that the concept of burden could be structured
around 5 components: autonomy, daily life, family and personal relationships,
work and psychological impact. 41 preliminary items were identified at the end of
the verbatim. A final analysis managed to reduce to 28 items and a cognitive de-
briefing allowed to ensure its reproducibility. CONCLUSIONS: Chronic pathologies
such as OA which remains a rare and incapacitating illness are difficult to assess by
clinical or QoL aspects alone as their impact can be multidimensional. “BONeS”
takes them all into consideration in order to explain every angle of the handicap
generated. Our next objective is to develop the “BONeS” in German, Italian and
Spanish with a cross cultural validation.
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OBJECTIVES: Atopic dermatitis is one of the most common chronic inflammatory
skin diseases. It has an estimated prevalence of between 5 and 30% in children, and
is steadily increasing in industrialized countries. Pruritus, xerosis and inflamma-
tion are the main symptoms. METHODS: The ABS questionnaire (Atopy Burden
Score) consists of 19 items, structured around 5 components (Everyday Life, Lei-
sure, Family Life, Budget, Work and Privacy). It was distributed to a random sample
of families consulting at the Necker Hospital. The ABS was accompanied by SF12
and PGWBI to obtain internal and external validation, and by the PO-SCORAD to
assess the level of severity. RESULTS: 58 were considered evaluable. Internal va-
lidity was measured by Cronbach’s alpha, which is equal to 0.81, reflecting a good
homogeneity of the 19 questionnaire items. The mean PGWBI score is 51.8214.28.
The scores are significantly different depending on the severity of the atopy. Fam-
ilies’ quality of life, measured using the SF12, revealed no deterioration in the
physical component (52.837.08). The ABS score is correlated with the scores of the
questionnaires used, thus confirming external validity.The mean score calculated
from the ABS is 48.1718.36. The score increases with the severity of the atopy.A
statistically significant difference is observed between the three severity groups,
i.e. mild, moderate and severe, with scores of 30.6310.89, 42.5515.72 and
62.6213.59 respectively. Each of the five components is also correlated with the
severity of atopy, which opens the door for more detailed analyses of sensitivity to
change. CONCLUSIONS: The internal and external validity of our questionnaire
were confirmed. ABS is correlated with the severity of atopy. This is currently being
done as part of a program aimed at evaluating the therapeutic education and
treatment of children in hydrotherapy centers. Following cultural and linguistic
validation, the ABS is now available in US English, Spanish, German and Italian.
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OBJECTIVES: The Alcohol Timeline Followback (TLFB), developed in English (US), is
a drinking assessment method that obtains estimates of daily drinking. Using a
calendar, people provide retrospective estimates of their daily drinking over a spec-
ified time period that can vary up to 12 months from the interview date. Several
memory aids can be used to enhance recall, such as 24 key dates and country
specific holidays for calendar year 2012 serving as anchors for reporting drinking,
or use of standard drink conversion. The objective of this study is to present the
translation of the TLFB in Czech, Slovak, Italian, and Hungarian. METHODS: The
following translation method was used: concept definition, forward translation in
the target languages, backward translation and test on five individuals (cognitive
interviews) in each country. RESULTS: Difficulties encountered during the process
were twofold: 1) ensuring that the standard drink conversions were correct, i.e.,
reflecting US standards, and culturally appropriate, and 2) adapting the 24 US key
anchor dates to each country. For the standard drink conversion, the main change
was the use of the metric system instead of the US customary units, i.e., use of liter
and sub-units instead of ounces. In addition, quantities had to be adapted to fit
cultural uses. For instance, in Slovakia and Czech Republic, “one 12 oz can/bottle of
beer” was adapted to “one beer in a can / bottle of 0.5 liter.” Thirteen anchor dates
in the US calendar had to be deleted in all countries, e.g., Martin Luther King day
(01/16/2012) or President’s Day (02/20/2012), as culturally inappropriate. Other key
dates were added, e.g., Labor Day (05/01/2012) or Easter Monday (04/09/2012) in all
four countries. Patients were key in discussing changes or proposing solutions.
CONCLUSIONS: The multistep process proved crucial to ensure cultural relevance
and cross-cultural equivalencies across different languages.
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OBJECTIVES: The Child Health Utility-9D (CHU9D) and Assessment of Quality of
Life-6D (AQOL-6D) currently represent the only two generic preferences based in-
struments developed for application in the economic evaluation of new health
technologies with both adult and adolescent specific scoring algorithms attached
to them. The main objective of this study was to compare and contrast the appli-
cation of adult and adolescent scoring algorithms for the CHU9D and AQOL-6D in
valuing the health of a community based sample of adolescents.METHODS:A web
based survey including the CHU9D and the AQOL-6D was developed for adminis-
tration to adolescents residing in Australia, aged 11-17 years (n500). Individual
responses to both instruments were converted to health state utility values by
applying [1] adult and [2] adolescent scoring algorithms pertaining to each
instrument. RESULTS: Both the AQOL-6D and CHU9D discriminated well according
to health status and long standing illness regardless of the scoring algorithm em-
ployed. However, important discrepancies were found in that employment of the
adolescent algorithm resulted in consistently lower mean health state values for
the CHU9D but consistently higher mean health state values for the AQOL-6D
relative to employment of their respective adult algorithms and these differences
were found to be statistically significant for both instruments (p0.05).
CONCLUSIONS: The findings from this study concur with an expanding evidence
base highlighting discrepancies in adult and adolescent values for identical health
states. The differences in adolescent and adult values were more profound for the
CHU9D, particularly in relation to mental health impairment states, and may be
significant enough to strongly affect the findings of cost effectiveness studies and
ultimately health care policy. There are important differences between both the
CHU9D and AQOL-6D descriptive systems and the methods of valuation utilized for
each instrument which may impact on the health state utility values generated by
each scoring algorithm.
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OBJECTIVES: To value SF-12v1 outcomes from the perspective of US adults
METHODS: The paired comparisons of the SF-12v1 items were incorporated into a
larger, online survey of US health preferences using an invitation-only panel of US
respondents. This pivoted discrete choice experiment (DCE) collected 28,080 re-
sponses on 408 pairs from 936 respondents. The quantal response model includes
an additive multi-attribute regression within a stacked logit distribution to allow
for excess kurtosis due to satisficing. RESULTS: On a quality-adjusted life year
scale, 30 out of 31 decrements were significantly non-zero at 0.05 significance level.
The only insignificant decrement, LE2, represented the decrease in energy from
“You have a lot of energy all of the time” (i.e., manic) to “You have a lot of energy
most of the time.” The value of pits was 0.1532 QALY (95% CI 0.1022,0.1970) and was
significantly better than dead (0). CONCLUSIONS: This is the first national valua-
tion study of the SF-12v1 descriptive system. Instead of reducing domains of com-
plex descriptive systems to single items (e.g., SF-36v1), DCE allows for choice-based
valuation of all outcomes, regardless of the number of items.
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OBJECTIVES: To undertake a detailed review of the existing use of utility scores in
models evaluating the cost-effectiveness of mental health conditions. The study
also aimed to identify the key issues and challenges that are faced by decision
makers attempting to evaluate the benefits of treatments for mental health.
METHODS: A detailed review was undertaken to identify a wide range of studies
that used modelling techniques to estimate the cost-effectiveness of interventions
for different mental health conditions. The review included studies of treatments
for bi-polar disorder, schizophrenia, depression, anxiety, dementia, eating disor-
ders. The review determined whether each model contained utility data and how
those utility data were derived and reported. Quality grades were assigned to each
study based on the appropriateness of use of the utility data. RESULTS: Nearly all
cost-effectiveness models in mental health contained utility-based outcomes,
such as quality-adjusted life years. However, the quality of data used to generate
those outcomes varied considerably, and many studies contained poor data or data
used in an inappropriate manner. In addition to the expected limitations of instru-
ments used to derive quality of life scores, common misuses of data included: 1)
inappropriate timing of elicitation (for instance, applying quality of life scores at
diagnosis to the whole duration of the model); 2) failing to account for comorbidi-
ties and confounding factors; 3) assumptions around missing data; and 4) failing to
account for the patient’s history when defining their current health state.
CONCLUSIONS: The use of utility data in mental health models varies widely, and
most models cannot be considered to provide reliable and robust data. For models
to be useful to decision makers, it is recommended that a consistent approach
toward measuring quality of life in patients with mental health conditions should
be used where possible.
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OBJECTIVES: In its guidance on the use of PRO measures, the FDA specifies the
areas to be addressed in PRO documents provided for review. Regarding language
translation, four areas are listed: (A) Process used to translate and culturally adapt
the instrument for populations that will use them in the trial; (B) Description of
patient testing, language- or culture-specific concerns, and rationale for decisions
made to create new versions; (C) Copies of translated or adapted versions; and (D)
Evidence that content validity and other measurement properties are comparable
between the original and new instruments. The objective of this study is to present
the development of an evidence tracking tool to organize the evidence generated
during the translation of a PRO instrument to comply with the FDA review
requirements. METHODS: 1) Review of the process used to translate PRO instru-
ments, and of the evidence provided during the translation process; 2) Organiza-
tion of the evidence according to the four areas listed in the FDA guidance (exclud-
ing measurement properties); and 3) Development of a standardized tool to present
this information.RESULTS:The translation evidence tracking tool is a table divided
into three parts. Part 1 (translation background information) gathers the informa-
tion requested in areas A and C. Part 2 (translation report) provides the evidence
required in area B. Part 3 (content validity) concerns the comparability of content
validity. For this part, it was assumed that comparability will depend on: (1) A clear
definition and understanding of the concepts to be translated; and (2) The involve-
ment of trained professionals. Hyperlinks are provided in each part of the table to
lead to the evidence documents required for each area listed by the FDA.
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